Meta-analysis of oxaliplatin-based versus fluorouracil-based neoadjuvant chemoradiotherapy and adjuvant chemotherapy for locally advanced rectal cancer
Metrics: PDF 1546 views | HTML 1555 views | ?
Xing-Li Fu3,*, Zheng Fang2,*, Liang-Hui Shu4,*, Guo-Qing Tao1, Jian-Qiang Wang5, Zhi-Lian Rui6, Yong-Jie Zhang2, Zhi-Qiang Tian1
1Department of General Surgery, Wuxi People's Hospital Affiliated Nanjing Medical University, Wuxi 214023, China
2Department of Biliary Surgery, The Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai 200438, China
3Health Science Center, Jiangsu University, Zhenjiang, Jiangsu 212001, China
4Department of Nephrology and Endocrinology, The 101st Hospital of Chinese PLA (Wuxi Taihu Hospital), Wuxi 214044, China
5The Second People’s Hospital of Jintan District, Changzhou, Jiangsu 213200, China
6The People’s Hospital of Liyang, Changzhou, Jiangsu 213300, China
*These authors contributed equally to this work
Zhi-qiang Tian, email: firstname.lastname@example.org
Yong-jie Zhang, email: email@example.com
Keywords: rectal cancer, neoadjuvant chemoradiotherapy, adjuvant chemotherapy, oxaliplatin, meta-analyses
Received: November 22, 2016 Accepted: February 22, 2017 Published: March 11, 2017
A meta-analysis was conducted to compare oxaliplatin-based with fluorouracil-based neoadjuvant chemoradiotherapy and adjuvant chemotherapy for locally advanced rectal cancer. MEDLINE, EMBASE and CENTRAL were systematically searched for relevant randomized controlled trials (RCTs) until January 31 2017. Review Manager (version 5.3) was used to analyze the data. Dichotomous data were calculated by odds ratio (OR) with 95% confidence intervals (CI). A total of 8 RCTs with 6103 stage II or III rectal cancer patients were analyzed, including 2887 patients with oxaliplatin+fluorouracil regimen and 3216 patients with fluorouracil alone regimen. Compared with fluorouracil-based regimen group, oxaliplatin-based regimen group attained higher pathologic complete response (OR = 1.29, 95% CI: 1.12−1.49, P = 0.0005) and 3-year disease-free survival (OR = 1.15, 95% CI: 0.93−1.42, P = 0.21), but suffered greater toxicity (OR = 2.07, 95% CI: 1.52−2.83, P < 0.00001). Also, there were no significant differences between two regimens in sphincter-sparing surgery rates (OR = 0.94, 95% CI: 0.83−1.06, P = 0.33), 5-year disease-free survival (OR = 1.15, 95% CI: 0.93−1.42, P = 0.21) and overall survival (3-year, OR = 1.14, 95% CI: 0.98−1.34, P = 0.09; 5-year, OR = 1.06, 95% CI: 0.78−1.44, P = 0.70). In conclusion, the benefits of adding oxaliplatin to fluorouracil-based neoadjuvant chemoradiotherapy and adjuvant chemotherapy for locally advanced rectal cancer remains controversial, and cannot be considered a standard approach.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.